BIOC Key Statistics, Chart & Performance
The current stock price of BIOC is 0.4349 USD. In the past month the price decreased by -69.16%. In the past year, price decreased by -98.23%.
BIOC Technical Analysis
BIOC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BIOC. BIOC has a bad profitability rating. Also its financial health evaluation is rather negative.
BIOC Financial Highlights
Over the last trailing twelve months BIOC reported a non-GAAP Earnings per Share(EPS) of -43.07. The EPS decreased by -42970% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -239.73% | ||
| ROE | -18271.38% | ||
| Debt/Equity | 4.7 |
BIOC Forecast & Estimates
6 analysts have analysed BIOC and the average price target is 4.08 USD. This implies a price increase of 838.15% is expected in the next year compared to the current price of 0.4349.
For the next year, analysts expect an EPS growth of 86.86% and a revenue growth -93.72% for BIOC
BIOC Ownership
BIOC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.87 | 382.02B | ||
| AMGN | AMGEN INC | 15.71 | 185.02B | ||
| GILD | GILEAD SCIENCES INC | 15.76 | 160.18B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.56 | 117.00B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.65 | 78.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 716.59 | 48.28B | ||
| INSM | INSMED INC | N/A | 33.34B | ||
| NTRA | NATERA INC | N/A | 33.51B | ||
| BIIB | BIOGEN INC | 10.31 | 25.32B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.72B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.8 | 20.23B | ||
| INCY | INCYTE CORP | 16.3 | 20.55B |
Related stock screener links
About BIOC
Company Profile
Biocept, Inc. is an oncology laboratory service company, which engages in the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company is headquartered in San Diego, California and currently employs 50 full-time employees. The company went IPO on 2014-02-05. The firm focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name CNSide. CNSide encompasses a suite of cellular and molecular technologies intended to aid medical professionals in CSF analysis and central nervous system (CNS) disease management in patients with solid tumors. The company offers and conducts its commercialized diagnostic assays, which include cell capture and enumeration, immunocytochemistry, fluorescent in situ hybridization (FISH), and next generation sequencing (NGS). The company has commercialized its CNSide assays for detecting and characterizing many different carcinomas and melanoma. These assays utilize its dual cellular and ctDNA technology platforms and provide biomarker analysis from a patient’s CSF sample.
Company Info
BIOCEPT INC
9955 Mesa Rim Road
San Diego CALIFORNIA 92121 US
CEO: Michael W. Nall
Employees: 50
Phone: 18583208200.0
BIOCEPT INC / BIOC FAQ
What does BIOC do?
Biocept, Inc. is an oncology laboratory service company, which engages in the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company is headquartered in San Diego, California and currently employs 50 full-time employees. The company went IPO on 2014-02-05. The firm focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name CNSide. CNSide encompasses a suite of cellular and molecular technologies intended to aid medical professionals in CSF analysis and central nervous system (CNS) disease management in patients with solid tumors. The company offers and conducts its commercialized diagnostic assays, which include cell capture and enumeration, immunocytochemistry, fluorescent in situ hybridization (FISH), and next generation sequencing (NGS). The company has commercialized its CNSide assays for detecting and characterizing many different carcinomas and melanoma. These assays utilize its dual cellular and ctDNA technology platforms and provide biomarker analysis from a patient’s CSF sample.
What is the current price of BIOC stock?
The current stock price of BIOC is 0.4349 USD. The price decreased by -13.05% in the last trading session.
Does BIOCEPT INC pay dividends?
BIOC does not pay a dividend.
What is the ChartMill technical and fundamental rating of BIOC stock?
BIOC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What do analysts say about BIOCEPT INC (BIOC) stock?
6 analysts have analysed BIOC and the average price target is 4.08 USD. This implies a price increase of 838.15% is expected in the next year compared to the current price of 0.4349.
What is BIOCEPT INC worth?
BIOCEPT INC (BIOC) has a market capitalization of 1.05M USD. This makes BIOC a Nano Cap stock.
When does BIOCEPT INC (BIOC) report earnings?
BIOCEPT INC (BIOC) will report earnings on 2023-11-20, after the market close.